Literature DB >> 1371482

Effects of imidazole derivatives on cytochromes P450 from human hepatocytes in primary culture.

M Maurice1, L Pichard, M Daujat, I Fabre, H Joyeux, J Domergue, P Maurel.   

Abstract

The expression of several forms of cytochrome P450 including P450 1A2, 2D6, 2E1, and 3A was investigated in human hepatocytes maintained in primary culture for 96 h in the absence or presence of 50 microM of various imidazole derivatives. These included ketoconazole, clotrimazole, miconazole, fluconazole, secnidazole and metronidazole. In addition, the typical inducers rifampicin and beta-naphthoflavone were used for comparison. Western and Northern blot analysis of microsomes and RNA prepared from these cultures as well as de novo synthesis experiments revealed that, among the imidazole derivatives tested, only clotrimazole was a strong rifampicin-like inducer of P450 3A. The expression of the other forms of P450 tested was not affected by the treatments. Analysis of the inhibition of 13 monoxygenase activities, including ethoxyresorufin and phenacetin O-deethylases, coumarin 7 alpha-, lauric acid 11- and 12-, mephenytoin 4-, debrisoquin 4-, and aniline hydroxylases, benzphetamine, aminopyrine, mephenytoin and erythromycin demethylases, and cyclosporin oxidase (representative of 10 different forms of P450 in human liver microsomes) revealed that ketoconazole was a strong and selective in vitro inhibitor of P450 3A (cyclosporin oxidase) with a Ki less than 1 microM. Clotrimazole and miconazole were also strong inhibitors of P450 3A-mediated activities in contrast to the other imidazole derivatives.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1371482     DOI: 10.1096/fasebj.6.2.1371482

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  45 in total

Review 1.  Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.

Authors:  K Venkatakrishnan; L L von Moltke; D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  2000-02       Impact factor: 6.447

2.  An examination of the effect of intestinal first pass extraction on intestinal lymphatic transport of saquinavir in the rat.

Authors:  Brendan T Griffin; Caitriona M O'Driscoll
Journal:  Pharm Res       Date:  2007-11-02       Impact factor: 4.200

3.  Assessment of the involvement of CYP3A in the vitro metabolism of a new modulator of MDR in cancer chemotherapy, OC144-193, by human liver microsomes.

Authors:  E S Guns; P L Bullock; M L Reimer; R Dixon; M Bally; L D Mayer
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2001 Oct-Dec       Impact factor: 2.441

Review 4.  The Mycobacterium tuberculosis cytochrome P450 system.

Authors:  Hugues Ouellet; Jonathan B Johnston; Paul R Ortiz de Montellano
Journal:  Arch Biochem Biophys       Date:  2009-07-25       Impact factor: 4.013

Review 5.  Genetic polymorphism of drug metabolizing enzymes: new mutations in CYP2D6 and CYP2A6 genes in Japanese.

Authors:  T Yokoi; T Kamataki
Journal:  Pharm Res       Date:  1998-04       Impact factor: 4.200

Review 6.  Cytochrome P450 3A: ontogeny and drug disposition.

Authors:  S N de Wildt; G L Kearns; J S Leeder; J N van den Anker
Journal:  Clin Pharmacokinet       Date:  1999-12       Impact factor: 6.447

7.  Fluoxetine inhibits the metabolism of tolterodine-pharmacokinetic implications and proposed clinical relevance.

Authors:  N Brynne; C Svanström; A Aberg-Wistedt; B Hallén; L Bertilsson
Journal:  Br J Clin Pharmacol       Date:  1999-10       Impact factor: 4.335

8.  Identification of the human cytochrome P450 enzymes involved in the in vitro metabolism of artemisinin.

Authors:  U S Svensson; M Ashton
Journal:  Br J Clin Pharmacol       Date:  1999-10       Impact factor: 4.335

Review 9.  Fluconazole. An update of its antimicrobial activity, pharmacokinetic properties, and therapeutic use in vaginal candidiasis.

Authors:  C M Perry; R Whittington; D McTavish
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546

10.  Identification of P450 enzymes involved in metabolism of verapamil in humans.

Authors:  H K Kroemer; J C Gautier; P Beaune; C Henderson; C R Wolf; M Eichelbaum
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-09       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.